Independent global research organization Frost & Sullivan honored Barco, a healthcare imaging solutions company, with the 2013 North American Product Line Strategy Award in Diagnostic Imaging Displays at the 2013 Growth, Innovation & Leadership Awards on Sept. 9, 2013 in San Jose, Calif. The award recognized Barco for delivering excellence and best practices in the North American diagnostic image displays market.

The North Shore-LIJ Health System Department of Radiation Medicine presented a study to evaluate the reliability of different systems used by caregivers to assess toxicity for patients receiving radiation therapy at the 55th Annual Meeting of the American Society of Therapeutic Radiation Oncology (ASTRO).

Proton therapy is the most advanced radiation technique available. Unfortunately, access to proton therapy is limited due to the low number of proton therapy centers. Research institutes and hospitals are now frequently investing in proton therapy to make it more accessible to patients.

The Thayer School of Engineering and Geisel School of Medicine at Dartmouth together with LI-COR Biosciences and Affibody AB announced a new partnership to establish an efficient pipeline for development and translation of molecularly targeted agents. The National Cancer Institute funds the five-year project.

Elekta unveiled a state-of-the-art learning center at its North American headquarters, in conjunction with the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO), which was held in Atlanta.

Methodist Le Bonheur Healthcare (MLH) will deploy McKesson’s portfolio of enterprise medical imaging products across its facilities to improve physician collaboration, streamline data management and simplify its imaging archive process with a single point of access.

October 2, 2013 — Between 1999 and 2002, the UK Standardization of Breast Radiotherapy (START) trials recruited 4,451 women from 35 radiotherapy centers across the U.K. START A compared the international standard, a total dose of 50 Gy delivered in 25 doses of 2 Gy over 5 weeks with 41.6 Gy of 3.2 Gy and 39 Gy of 3 Gy given in 13 treatments over 5 weeks. START B compared the standard (50 Gy given in 25 doses of 2 Gy over 5 weeks) with 40 Gy delivered in 15 doses of 2.67 Gy over 3 weeks (hypofractionated).

To clear confusion, reduce unnecessary breast cancer deaths and help women avoid extensive treatment for undetected advanced cancers, the Mammography Saves Lives (MSL) coalition has launched a new series of television and radio public service announcements (PSAs) informing women ages 40 and older to get annual mammograms at nearby mammography centers.